home / stock / cere / cere news


CERE News and Press, Ceres Inc. From 02/10/24

Stock Information

Company Name: Ceres Inc.
Stock Symbol: CERE
Market: NASDAQ
Website: ceres.org

Menu

CERE CERE Quote CERE Short CERE News CERE Articles CERE Message Board
Get CERE Alerts

News, Short Squeeze, Breakout and More Instantly...

CERE - Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

2024-02-10 20:30:24 ET Summary Neurocrine Biosciences' shares have sold off post-earnings on concerns about its near-term opex spending and slowing growth for lead drug Ingrezza. Higher-than-expected opex spending includes targeted spending to grow the Ingrezza business (Huntingto...

CERE - Catalyst Watch: Coca-Cola earnings, Instacart lockup, 13F filings and more NYCB drama

2024-02-09 15:00:09 ET More on the markets SPY: Larger Treasury Issuances And Fewer Fed Cuts Are Not Priced In My Current View Of The S&P 500 Index: February 2024 Edition (Technical Analysis) 2024 Analyst Outlook: Yiannis Zourmpanos On Cautious Optimism For The N...

CERE - Long Term Trading Analysis for (CERE)

2024-02-08 05:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CERE - AbbVie: Game Changer

2024-02-06 16:05:44 ET Summary AbbVie Inc. is showing signs of growth beyond the loss of exclusivity for Humira, with strong 2024 guidance. Sales of Skyrizi and Rinvoq are replacing lost Humira sales, with projected sales more than doubling through 2027. AbbVie's acquisitions ...

CERE - AbbVie posts Q4 revenue beat despite Humira patent cliff

2024-02-02 08:22:44 ET More on AbbVie AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade) AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen AbbV...

CERE - AbbVie Q4 in focus as Humira patent cliff reaches one-year mark

2024-02-01 12:10:01 ET More on AbbVie AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade) AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen AbbV...

CERE - AbbVie raised to Outperform at William Blair ahead of earnings

2024-01-29 08:30:18 ET More on AbbVie AbbVie Inc. (ABBV) JPMorgan 42nd Annual Healthcare Conference AbbVie: Still Expensive Despite The Great M&A Acumen Investor's Dilemma: AbbVie Stock Amidst U.S. Election And Humira Decline Big Pharma earnings season in...

CERE - When the Price of (CERE) Talks, People Listen

2024-01-28 12:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CERE - SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, CERE, PGTI, FGH

NEW YORK, NY / ACCESSWIRE / January 27, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CapStar Financial Holdings, Inc...

CERE - AbbVie: Still Expensive Despite The Great M&A Acumen

2024-01-05 09:00:00 ET Summary ABBV's Humira erosion has been well balanced by the robust growth reported by Skyrizi and Rinvoq, implying its ability to maintain a stable top/ bottom line performance ahead. The management has also participated in the aggressive M&A activities ...

Previous 10 Next 10